LOGIN  |  REGISTER
Surmodics
Compass Therapeutics

Veracyte to Participate in Upcoming Investor Conferences

May 23, 2023 | Last Trade: US$19.31 0.17 -0.87

SOUTH SAN FRANCISCO, Calif. / May 23, 2023 / Business Wire / Veracyte, Inc. (Nasdaq: VCYT) announced today that Marc Stapley, chief executive officer, and Rebecca Chambers, chief financial officer, will participate in two upcoming investor conferences:

  • William Blair 43rd Annual Growth Stock Conference – Chicago, IL
    Presentation on June 6th at 9:40 a.m. Eastern Time
  • Goldman Sachs 44th Annual Global Healthcare Conference – Dana Point, CA
    Fireside Chat on June 13th at 6:20 p.m. Eastern Time

Live audio webcasts of the company’s presentations will be available by visiting Veracyte’s website at http://investor.veracyte.com/events-presentations. A replay of the webcasts will be available for 90 days following the conclusion of the live presentation broadcast.

About Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our high-performing tests enable clinicians to make more confident diagnostic, prognostic, and treatment decisions for some of the most challenging diseases such as thyroid, prostate, breast, bladder and lung cancers, as well as interstitial lung diseases. We help patients avoid unnecessary procedures and speed time to diagnosis and appropriate treatment. In addition to making our tests available in the U.S. through our central laboratories, we also aim to deliver our tests to patients worldwide through a distributed model to laboratories that can perform them locally. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).

Stock Quote

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB